DUBLIN--(BUSINESS WIRE)--The "Pharmaceutical Contract Manufacturing Market (2nd Edition), 2018-2028" report has been added to ResearchAndMarkets.com's offering.
The Pharmaceutical Contract Manufacturing Market (2nd Edition), 2018-2028' report provides a comprehensive study on the current scenario of contract manufacturing services related to pharmaceutical products. The study features an in-depth analysis, highlighting the capabilities of a diverse set of pharmaceutical CMOs.
The present pipeline of pharmaceutical products is increasingly complex and requires specialized facilities, equipment and operational expertise.
Small molecule drugs account for nearly 90% of the therapeutics in the pharmaceutical market. In fact, in 2017, FDA's Center for Drug Evaluation and Research approved 34 small molecule drugs; this represents an annual growth of nearly 56%, signifying the growing importance of contract manufacturing in the overall pharmaceutical industry.
The costs associated with acquiring manufacturing capabilities are exorbitant and, therefore, it is difficult for companies with limited finances and capacity constraints to succeed by themselves. The aforementioned constraints have led many of the smaller players in the industry and, at times, certain pharma giants as well, to outsource a significant part of their business operations to contract service providers. Third-party service providers are known to offer significant cost-benefits, access to larger production capacities and reductions in time-to-market.
Over the years, the contract manufacturing market has grown into a prominent and promising segment of the overall pharmaceutical industry. Since 2000, close to 150 new CMOs have been established, offering cost-efficient solutions to several stakeholders in the industry.
The current global CMO market is highly fragmented but characterized by multiple acquisitions and mergers as stakeholders strive to broaden their respective service portfolios. This has enabled several CMOs to start offering end-to-end services, ranging from drug development, including preliminary R&D, preclinical and clinical trials, to commercial scale production and regulatory filings.
Despite the fact that the pharmaceutical sector is amongst the most highly regulated industries, we expect the demand for core competencies to continue to drive sponsor companies to outsource various parts of their manufacturing operations. Amidst tough competition, the availability of advanced tools and technologies is an important differentiating factor and will grant a competitive edge to certain CMOs over other stakeholders in the industry.
However, given the ongoing innovation in production technologies and the steadily evolving pipeline of small molecules, the pressure on the contract manufacturing industry is expected to increase in the coming years. This is likely to require CMOs to devise and implement different business strategies and models in order to cope with the evolving demand.
Key Topics Covered:
2. Executive Summary
4. Competitive Landscape
5. Regulatory Landscape For Pharmaceutical Contract Manufacturers
6. Company Profiles
7. Case Study: Comparison Of Small Molecules And Large Molecules
8. Key Insights
9. Capacity Analysis
10. Market Forecast
11. Swot Analysis
12. Future Of The Pharmaceutical Contract Manufacturing Market
13. Executive Insights
14. Appendix 1: Tabulated Data
15. Appendix 2: List Of Companies And Organizations
For more information about this report visit https://www.researchandmarkets.com/research/bqt2rw/global?w=4